Natera (NTRA)

Executive Summary

Natera is a global leader in cell-free DNA (cfDNA) testing, with a strong focus on oncology, women's health, and organ health. The company's proprietary platform, including Signatera for molecular residual disease (MRD) detection and Prospera for organ transplant monitoring, has driven significant commercial adoption. With over 16 million tests processed and a CAP/CLIA-certified laboratory, Natera continues to expand its test menu and reimbursement coverage. The company's recent financial performance has been bolstered by growing volumes in its core oncology franchise, particularly Signatera for colorectal and breast cancers. Looking ahead, Natera is well-positioned to capitalize on the expanding liquid biopsy market, with several near-term catalysts that could drive further upside. The company's robust pipeline and strategic initiatives support a positive outlook, though competitive pressures and reimbursement dynamics remain key factors to monitor.

Upcoming Catalysts (preview)

• Q3 2026FDA Approval of Signatera for Bladder Cancer80% success
• Q4 2026Expansion of Medicare Coverage for Liquid Biopsy in Lung Cancer Screening60% success
• TBDLaunch of Multi-Cancer Early Detection Test (Galleri-like)30% success